Tailoring Dual Antiplatelet Therapy for the Complex PCI Patient: Current Status and Perspectives
- 29 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 34 (5), 697-706
- https://doi.org/10.1007/s10557-020-07009-6
Abstract
Dual antiplatelet therapy (DAPT) duration in patients undergoing percutaneous coronary intervention (PCI) has long been considered a matter of controversy. Complex-PCI (C-PCI) is considered to be associated with an increased ischemic risk that tends to be greater with progressively higher procedural complexity. Thus, with a view to balance ischemic versus bleeding risks, high complexity of PCI intuitively represents an advocate of prolonged DAPT duration. However, the optimal DAPT strategy in this high ischemic risk subset of patients remains unclear, a fact that is exacerbated by the absence of a universal definition of C-PCI, resulting in a significant between-study heterogeneity. The aim of this review is to highlight the increased risks associated with C-PCI, compare long- versus short-term DAPT regimens regarding safety and efficacy endpoints as well as investigate outcomes in special C-PCI cohorts, such as patients with bifurcation, left main or chronic total occlusion lesions. Furthermore, controversial issues, such as antithrombotic regimens in C-PCI patients with atrial fibrillation, and future perspectives are addressed.Keywords
This publication has 35 references indexed in Scilit:
- Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCIJournal of the American College of Cardiology, 2016
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionJAMA, 2016
- Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting StentsJournal of the American College of Cardiology, 2016
- 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery DiseaseJournal of the American College of Cardiology, 2016
- Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy durationEuroIntervention, 2016
- Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI surveyEuroIntervention, 2015
- Five-Year Follow-Up of Patients Treated for Coronary Artery Disease in the Face of an Increasing Burden of Co-Morbidity and Disease Complexity (from the NHLBI Dynamic Registry)The American Journal of Cardiology, 2013
- Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?American Heart Journal, 2013
- The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents: A Substudy of the RESOLUTE All Comers Trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)Journal of the American College of Cardiology, 2011
- Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry)The American Journal of Cardiology, 2002